Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

XRN vs SBRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SBRA Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

SBRA Overall Winner 6-Pillar Tally: XRN 0 – 6 SBRA Matrix Metrics: XRN 0 – 10 SBRA

As of Nov 17, 2026, Sabra Healthcare REIT, Inc. (SBRA) is the stronger overall head-to-head candidate over XRN (XRN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XRN carries a Unified Composite Score of 45.3/100 (HOLD) at $25.79 (N/M Forward P/E, N/A operating margin), whereas SBRA carries 57.4/100 (HOLD) at $20.27 (30.4x Forward P/E, 18.4% operating margin).

  • Technical & Structure Timing Caution: XRN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5); meanwhile SBRA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XRN vs SBRA
XRN US Equity
XRN
Institutional Equity
$25.79
-2.35% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.50β · 47% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 45.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 28
RSI-14: 28.5 · SMA20: $28.74 · SMA50: $32.14
SBRA NASDAQ Head-to-Head Winner
Sabra Healthcare REIT, Inc.
Real Estate Investment Trusts
$20.27
-0.37% 1D
Market Cap $5.4B
TTM Revenue $924M
Forward P/E 30.4x
Beta / 30D Vol 0.00β · 30% Vol
Unified Composite Score
57.4 / 100 HOLD
Tech 49.0 Fund 57.0 Flow 57.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.8 · SMA20: $20.21 · SMA50: $19.86

6-Pillar Scorecard Institutional Category Breakdown (XRN 0 – 6 SBRA)

Columns: Metric · XRN · SBRA
1. Valuation Multiples SBRA
Forward P/E N/M 30.4x
Trailing P/E N/M 75.7x
PEG Ratio N/M 5.28x
EV / Revenue N/M 8.4x
2. Growth & Scale SBRA
Revenue Growth (YoY) N/A +31.6%
Earnings Growth (YoY) N/A +22.2%
TTM Revenue (USD) N/A $924M
Market Cap N/A $5.4B
3. Profitability & Quality SBRA
Gross Margin N/A 49.6%
Operating Margin N/A 18.4%
Net Profit Margin N/A 7.7%
Return on Equity (ROE) N/A 2.5%
4. Balance Sheet & Cash Flow SBRA
Cash Generation (TTM) N/A $401M
Cash Flow Margin N/A 43.3%
Net Cash / Leverage N/A ROE $2.42B Net Debt (0.86x D/E)
Dividend Yield None (0.00%) 5.92%
5. Options & Positioning SBRA
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 27.4% (17th %ile)
Put/Call OI Skew N/A 0.19x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat SBRA
OpEx & R&D Intensity N/A 31.2% of Rev ($288M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Institutional Equity Operator REIT - Healthcare Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XRN (0) vs SBRA (10)
Institutional Metric XRN SBRA Criterion Row Edge
Market Capitalization
Scale
N/A $5.4B Larger Scale SBRA
Trailing P/E Ratio
Valuation
N/M 75.7x Lower Multiple SBRA
Forward P/E Ratio
Valuation
N/M 30.4x Lower Multiple SBRA
Revenue Growth (YoY)
Growth
N/A +31.6% Higher Growth SBRA
Operating Margin (TTM)
Profitability
N/A 18.4% Higher Margin SBRA
Net Profit Margin
Profitability
N/A 7.7% Higher Margin SBRA
Return on Equity (ROE)
Capital Efficiency
N/A 2.5% Higher ROE SBRA
52-Week Range Position
Momentum
1% ($26–$39) 52% ($18–$23) Stronger Trend SBRA
Beta / 30D Volatility
Risk Regime
0.50β · 47% Vol 0.00β · 30% Vol Lower Realized Risk SBRA
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 57.4 / 100 (HOLD) Higher Composite SBRA
Trailing 12M Revenue (USD)
Operating Scale
N/A $924M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 49.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 5.28x PEG · 8.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $401M ($2.42B Net Debt (0.86x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SBRA +19.28 pp
XRN: -13.02% · SBRA: +6.26%
3M Horizon SBRA +28.76 pp
XRN: -30.05% · SBRA: -1.29%
6M Horizon SBRA +21.4 pp
XRN: -24.9% · SBRA: -3.5%
1Y Horizon SBRA +27.4 pp
XRN: -28.16% · SBRA: -0.76%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XRN vs SBRA. Trailing 12-month operating profitability (XRN N/A vs SBRA 18.4%) and valuation multiples (XRN N/M vs SBRA 30.4x Forward P/E) are benchmarked directly in Pillar 4 below.

XRN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
SBRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$924M
Gross Margin49.6%
Op. Margin18.4%
ROE / Fwd P/E2.5% · 30.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XRN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XRN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SBRA CONSOLIDATION
80d in phase · OBV DISTRIBUTION
Current IV 27.4%
IV Percentile 17th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SBRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XRN Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SBRA Moat Profile Scale & Operating Efficiency Moat
REIT - Healthcare Facilities Operator
Competes within the REIT - Healthcare Facilities value chain with $5.4B market capitalization and 18.4% operating margin.
OpEx & R&D Reinvestment 31.2% of Rev ($288M)
90D Engineering Disclosures 0 Published

Investor FAQ XRN vs SBRA Key Questions & Quantitative Answers

As of Nov 17, 2026, Sabra Healthcare REIT, Inc. (SBRA) is the stronger overall head-to-head candidate over XRN (XRN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XRN carries a Unified Composite Score of 45.3/100 (HOLD) at $25.79 (N/M Forward P/E, N/A operating margin), whereas SBRA carries 57.4/100 (HOLD) at $20.27 (30.4x Forward P/E, 18.4% operating margin). Technical & Structure Timing Caution: XRN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5); meanwhile SBRA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SBRA leads the Growth & Scale pillar: XRN posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SBRA at +31.6% YoY revenue growth and +22.2% YoY earnings growth on $924M TTM revenue (49.6% gross margin, 18.4% operating margin). On trailing 12-month operating scale, XRN generates N/A in USD-normalized revenue versus $924M for SBRA. In operating R&D and SG&A reinvestment, XRN deploys N/A (0 90-day corporate R&D disclosures) versus 31.2% of Rev ($288M) (0 disclosures) for SBRA.

SBRA screens cheaper on headline valuation multiples. XRN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SBRA trades at 30.4x Forward P/E, 75.7x Trailing P/E, 5.28x PEG, and 8.4x EV/Revenue (43.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XRN (N/A ROE) versus SBRA (2.5% ROE) capital efficiency.

In options market volatility and institutional positioning, XRN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.50β · 47% Vol realized risk). By comparison, SBRA carries 27.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.00β · 30% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.